Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 13/20 | 0.57 |
| ▸ | CDK9 | P50750 | 13/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994070 | 0.89 | CCNT1 (0.51) | CCNT1CDK9TBK1PDE10AGRM5 | |
| SCHEMBL5661075 | 0.88 | CCNT1 (0.49) | CCNT1CDK9 | |
| SCHEMBL14500354 | 0.86 | CDK9 (0.55) | CCNT1CDK9TBK1 | |
| SCHEMBL14500302 | 0.86 | CDK9 (0.57) | CCNT1CDK9TBK1 | |
| SCHEMBL14500359 | 0.86 | CCNT1 (0.55) | CCNT1CDK9TBK1PDE10A | |
| SCHEMBL5661370 | 0.85 | CDK9 (0.56) | CCNT1CDK9TBK1 | |
| SCHEMBL14500303 | 0.85 | CDK9 (0.56) | CCNT1CDK9TBK1 | |
| SCHEMBL14500458 | 0.85 | CDK9 (0.56) | CCNT1CDK9TBK1 | |
| SCHEMBL5661540 | 0.85 | CDK9 (0.56) | CCNT1CDK9TBK1PDE10A | |
| SCHEMBL14500243 | 0.85 | CDK9 (0.59) | CCNT1CDK9TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CCNT1 1682/4885CDK9 392/4885TBK1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.